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Object: Low-field intraoperative magnetic resonance (LF-iMR) has demonstrated a slight
increase in the extent of resection of intra-axial tumors while preserving patient`s
neurological outcomes. However, whether this improvement is cost-effective or not is
still matter of controversy. In this clinical investigation we sought to evaluate the cost-
effectiveness of the implementation of a LF-iMR in glioma surgery.
Methods: Patients undergoing LF-iMR guided glioma surgery with gross total resection
(GTR) intention were prospectively collected and compared to an historical cohort
operated without this technology. Socio-demographic and clinical variables (pre and
postoperative KPS; histopathological classification; Extent of resection; postoperative
complications; need of re-intervention within the first year and 1-year postoperative
survival) were collected and analyzed. Effectiveness variables were assessed in both
groups: Postoperative Karnofsky performance status scale (pKPS); overall survival (OS);
Progression-free survival (PFS); and a variable accounting for the number of patients with
a greater than subtotal resection and same or higher postoperative KPS (R-KPS). All
preoperative, procedural and postoperative costs linked to the treatment were considered
for the cost-effectiveness analysis (diagnostic procedures, prosthesis, operating time,
hospitalization, consumables, LF-iMR device, etc). Deterministic and probabilistic
simulations were conducted to evaluate the consistency of our analysis.
Results: 50 patients were operated with LF-iMR assistance, while 146 belonged to the
control group. GTR rate, pKPS, R-KPS, PFS, and 1-year OS were respectively 13,8% (not
significative), 7 points (p < 0.05), 17% (p < 0.05), 38 days (p < 0.05), and 3.7% (not
significative) higher in the intervention group. Cost-effectiveness analysis showed a mean
incremental cost per patient of 789 € in the intervention group. Incremental cost-
effectiveness ratios were 111 € per additional point of pKPS, 21 € per additional day
free of progression, and 46 € per additional percentage point of R-KPS.
Conclusion: Glioma patients operated under LF-iMR guidance experience a better
functional outcome, higher resection rates, less complications, better PFS rates butNovember 2020 | Volume 10 | Article 5866791
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very close to be a dominant technology in terms of R-KPS, PFS and pKPS.Keywords: cost-effectiveness, glioma, incremental cost-effective ratio, intraoperative magnetic resonance,
technology assessment, Karnofsky performance status, progression-free survival (PFS)INTRODUCTION
Primary brain tumors may manifest with a wide range of signs
and symptoms such as seizures, headache, neurological deficits,
and endocrinological disturbances, alone or in combination. The
most frequent and malignant primary brain tumor in adults is
the Glioblastoma (GBM), a subtype within the group of high-
grade gliomas (HGG) (1). The therapeutic algorithm for these
malignant neoplasms consists of a combination of surgery,
chemotherapy, and radiotherapy, together with some new
emergent treatments (2). Besides other prognostic factors such
as Karnofsky performance status (KPS), histology, and molecular
markers; the extent of resection (EoR) is a major prognostic
factor for overall survival (OS) and progression-free survival
(PFS) in this subset of malignant gliomas (3, 4). Recently, some
authors have reported the benefits of supramarginal resection in
the clinical outcome of HGG patients (5). Moreover, during the
last decade, substantial evidence has been accrued to support the
relevance of maximal or supramarginal resection in low-grade
gliomas (LGG) (6, 7). In this sense, several studies have proved
the role of surgery in the control of seizures, OS, and PFS for
LGG (6, 8, 9). All in all, EoR plays a major role in the treatment
and clinical course of patients diagnosed with either grade
of glioma.
Therefore, maximal safe resection is a major goal in LGG and
HGG treatment. Over the last decades neurosurgeons have
considerably improved their outcomes pushing the boundaries
of which had been considered feasible. These advancements have
been supported by a significant technological development.
Regarding glioma surgery the main innovations occurred in
the field of intraoperative image where intraoperative magnetic
resonance (iMR); ultrasonography and 5-ALA fluorescence
guided surgeries gained momentum becoming a sign of
excellence (10). Specifically, iMR guided surgery has
consistently demonstrated an increment in the rates of gross
total resection (GTR) without a negative impact in neurological
outcomes. This being said, the evidence that links this rise in
resection rates with an improvement in OS and PFS is poor or, in
other words, indirect (3, 10, 11).
Consequently, the general adoption of these devices is
supported by low quality evidence. Moreover, cost analysis of
the effectiveness of iMR in glioma surgery has not been
thoroughly conducted. Economic evaluation consists of the
comparison of costs and health benefits of alternative
interventions. Its ultimate goal is to provide information for
decision makers who, in a scarce resource context, ought to make
justified investment decisions based on the health improvements
that are obtained. Novel technologies often yield better health
outcomes entailing higher costs. The economic evaluation,
through cost-effectiveness analyses, estimate the incremental2
cost per unit of health effectiveness gained by a given
technology. Although the economic impact of the current
technological escalade is often disregarded by neurosurgeons, it
actually is a paramount issue that should be addressed to
maintain surgical excellence. Nonetheless, nowadays, there are
not scientifically proven advantages, neither in terms of cost
savings, clinical efficacy nor in cost-effectiveness to establish iMR
as a state-of-the-art asset in glioma surgery.
In this clinical research, we sought to assess the economic impact
of the implementation of a low field iMR (LF-iMR) device in glioma
surgery. Then, we compare the cost and clinical outcomes of two
different cohorts of patients, one treated with LF-iMR assistance and
another one operated in a conventional fashion.METHODS
The present clinical investigation was designed as a hybrid study
in which a prospectively recruited cohort was compared to an
historic cohort. The latter (control cohort) was made up with
consecutive patients treated from LGG (Pilocytic Astrocytoma,
Diffuse astrocytoma, Oligodendroglioma, Pleomorphic
Xanthoastrocytoma, Chordoid Glioma, and Angiocentric
glioma), HGG (Glioblastoma, Anaplastic astrocytoma,
Anaplastic oligodendroglioma, and Gliosarcoma) with a
maximal safe resection intention between 2010 and 2013 at
our institution. The prospective (intervention) cohort consisted
of patients operated of LGG and HGG with a maximal safe
resection intention with the assistance of a LF-iMR (PoleStar N-
20, Odin Medical Technologies, Yokneam, Israel and Medtronic,
Louisville, CO, USA). These patients were recruited between
June 2013, date of the installation of the device, and June 2016.
Tumors near eloquent areas were not excluded in either cohort.
The present research was approved by the institutional review
board (HCB/2013/8782). Patients signed an informed consent
before surgery agreeing the use of the LF-iMR; the review and
analysis of their clinical records; and the publication of the
results derived from this research.
The present report adheres to the recommendations of the
ISPOR Task Force and the guidelines contained in the document
named Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) for economic evaluations of health
interventions (12).
Surgical Technique
The retrospective group was operated using conventional
microsurgery, which could include the use of an ultrasonic
aspirator and standard neuronavigation. Patients operated with
any other intraoperative image assistance or intraoperative
fluorescence were excluded. The surgical workflow for the LF-November 2020 | Volume 10 | Article 586679
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neurophysiologic monitoring was implemented in both cohorts,
according to the decision of the surgical team. Neurophysiologic
criteria for stopping the resection remained unchanged across
the time of the present study.
Extent of Resection
EoR was defined under the following thresholds: GTR if 100% of
the mass was removed; Subtotal resection if more than 90% of
the mass was removed; anything else under this value was
considered a partial resection (PR) or a biopsy. In HGG, the
mass volume considered to evaluate the EoR was the
corresponding to the contrast enhancing part of the lesion. In
LGG, the whole T2/FLAIR hyperintense volume was considered.
Cost-Effectiveness
A cost-effectiveness analysis comparing conventional
microsurgery and LF-iMR guided surgery was conducted.
Socio-demographic (age and gender) and clinical variables [pre
and postoperative KPS (pKPS), histopathological classification,
EoR; postoperative complications, need of re-intervention within
the first year, 1-year progression-free survival (PFS), and 1-year
postoperative survival] were analyzed in both groups. One-year
PFS was computed as the time in days from surgery to the first
radiological exam demonstrating progression or recurrence
within the first year of follow-up. Patients with progressions or
recurrences later than one year were censored at 365 days. In
those patients in which resections were partial, recurrence or
progressions were considered when the tumor demonstrated
growth or novel malignant features compared to the residual
postoperative tumor. Postoperative complications included local
(intraparenchymal haemorrhage, wound, and surgical site
infection), neurological (new neurological deficits, new onset
seizures, hydrocephalus, ischemic stroke, and symptomatic
cerebral oedema), and systemic (cardiac infarction, deep
venous thrombosis, and pulmonary thromboembolism)
complications. Patients were followed-up for a minimum of 2
years after surgery.
We extracted the resource use of every single patient from the
hospital administrative database, and then we associated the
corresponding unit cost to each resource use in order to compute
the cost per individual patient. The collected resource use were:
operating time (in minutes); hospitalization in the intensive care
unit in days (ICU) which includes wages of involved
professionals and consumables (meals, medicines, etc.);
prosthesis (which includes dural substitutes, miniplates, sterile
covers and drapes, etc.); cost of the LF-iMR device; type and
number of radiological images performed one year after the
intervention and length of stay (LoS) in days (see Table 1). The
cost in Euros-2018 of these resources was pooled for further
analysis. No discount rate was considered due to the short time
frame of the analysis (16).
In order to define the cost of LF-iMR imputed to each patient
we did not only consider the surgeries object of the current
analysis. Conversely, we inferred the cost per patient from all the
indications in which we currently use the LF-iMR: intrinsic and
extrinsic brain lesions, cavernomas, pituitary macroadenomasFrontiers in Oncology | www.frontiersin.org 3and epilepsy surgery. Thus, the cost of the device per patient was
calculated considering a life cycle of 10 years and a potential
number of 120 surgeries per year [50 oncological surgeries (13,
15), 30 pituitary macroadenomas resection (14), 20 cavernous
malformations resections, 20 epilepsy surgeries] (Table 1).
A descriptive analysis of socio-demographic, clinical, and
resource usage variables was conducted. These variables were
compared by a t-test to discard significant differences between
groups. Patient’s specific data were pooled to compare
effectiveness, costs, and outcomes between groups. As
effectiveness variables mean postoperative KPS, 1-year OS and
1-year PFS were considered. In addition, a combined clinical
variable named R-KPS was created to assess effectiveness. This
dichotomic variable was used to classify patients onto two
categories, one for those with total or subtotal resections and
conserved or improved KPS and another one for those with
whichever degree of resection and a worsening in the KPS. TheTABLE 1 | Resource use and unit costs.
Resource use Probability
distributiona
Unit
costsb
Conventional
OR
LF-iMR
OR
Time in minutes
[mean (SD)]
368 (75) 415 (70) Gamma 5 €
Surgical pack [%
(n)]
100 (146) 100 (50) n.v. 1,150 €
Navigation system
[%o(n)]
0 (0) 100 (50) n.v. 862 €
Prosthesis [% (n)] 92 (134) 88 (44) Beta 272 €
LF-iMR [% (n)] 0 (0) 100 (50) n.v. 1M €c
833 €d
ICU
% (n) 67 (98) 34 (17) Beta 555 €
Preoperative
images [mean
(SD)]
MR-C 1.2 (0.9) 1.0 (0.9) Gamma 203 €
MR 2.0 (1.63) 1.7 (1.7) 138 €
PET 0.1 (0.2) 0.1 (0.3) 566 €
X-Ray 1.3 (1.6) 1.1 (1.2) 15 €
Portable XRay 0.03 (0.2) 0.1 (0.5) 32 €
CT 0.5 (0.6) 0.4 (0.6) 72 €
Postoperative
images [mean
(SD)]
MR-C 3.0 (1.7) 2.5 (1.7) Gamma 203 €
MR 3.5 (1.8) 3.1 (1.6) 138 €
X-Ray 1.1 (2.9) 1.7 (3.5) 15 €
Portable XRay 0.9 (1.2) 0.3 (0.9) 32 €
SPECT 0.1 (0.1) 0.1 (0.3) 166 €
CT 1.1 (2.9) 0.7 (1.4) 72 €
Hospitalization
Length of stay in
days [mean (SD)]
11.9 (7.8) 9.7 (5.4) Gamma 422 €November 2020 | Volume 10 | ArticleICU, Intensive care unit hospitalization; MR-C, magnetic resonance with contrast; M,
Million; n.v., not varied; OR, operating room.
aProbability distribution of every resource use parameter.
bAll cost parameters were varied using the Gamma distribution.
cTotal cost of the iMR device.
dCost per intervention using iMR based on the life cycle (10 years) and the potential
number of patients (n = 120) who yearly benefit from the iMR device.586679
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conserved or improved KPS was considered as an additional
effectiveness variable.
Costs were computted as the mean costs per patient. Mean
incremental effectiveness and costs were calculated for each
surgical group. Mean incremental effectiveness was calculated
as the difference between the mean effectiveness of the LF-iMR
and the conventional microsurgery. The same operation was
implemented to calculate mean incremental costs. Finally, the
cost-effectiveness analysis was summarized as the incremental
cost-effectiveness ratio (ICER), defined as the incremental cost
divided by the incremental effectiveness of two studied
alternatives (17). The cost-effectiveness analysis took a hospital
perspective considering only direct health costs incurred by
the hospital.
Deterministic and probabilistic sensitivity analyses (PSAs)
were conducted to evaluate the robustness of the results of the
cost-effectiveness analysis. The deterministic analysis compares
the results (ICERs) of the base case with various hypothetic
scenarios to test the consistency of our results. Three different
scenarios were built in which the effectiveness and the cost
parameters of the intervention group were shifted to the
extreme values (mean ± standard deviation). Then, a new
ICER was calculated for each scenario. Scenario A was created
to simulate a conservative situation in which the worst possible
clinical outcomes in the LF-iMR group would be obtained.
Conversely, Scenario B was built to offer a favorable scenario
assuming the best possible clinical outcomes of this new
technology. In Scenario C, clinical variables remained
unchanged while the results in terms of costs were taken to a
propitious setting in which the cost of the LF-iMR was reduced
by 20% of the average price. Finally, in Scenario D, a sub-
group analysis was conducted exclusively considering the
HGG cohort.Frontiers in Oncology | www.frontiersin.org 4To characterize the uncertainty of the model, we undertook a
PSA using Monte Carlo simulation. We applied probability
distributions to each parameter depending on its nature
according to the Economic Evaluation Guidelines (17–19). The
PSA was graphically represented by means of the cost-
effectiveness planes.
Calculations were performed using Microsoft Excel XP™.
Level of significance was set at p < 0.05.RESULTS
The sample (N = 196) demonstrated a slight male predominance
(60.7%) and an average age of 54 years. The majority of tumors
(69.4%) were classified under the label of HGG. Mean
preoperative KPS was rather favorable (score = 85). No
statistically significant differences in demographic nor in
clinical variables were found between groups (Table 2).
Clinical Outcomes
The use of the LF-iMR, compared to conventional microsurgery,
provided a higher percentage of patients with a GTR and a lower
percentage of patients presenting with postoperative
complications. Despite this positive trend related to the
implementation of the LF-iMR, no statistically significant
differences were found between groups regarding the EoR.
Patients undergoing LF-iMR guided surgery presented a
significant higher pKPS than those operated in a conventional
fashion (84 vs.77; Standard Deviation (SD): 9; p < 0.000). One-
year OS was higher for patients in the intervention group (88%
vs. 85%; p > 0.05) while 2-years OS was lower (70% vs. 73.3%; p >
0.05). Regarding PFS a significant improvement was found in the
LF-iMR cohort (333 days vs. 295 days; p = 0.025). A comparison
between PFS distributions for both cohorts was conducted usingTABLE 2 | Socio-demographic and clinical variables.
Conventional ORn = 146 LF-iMRn = 50 p Total
Gender Female (n, %) (57, 39) (20, 40) 0.892 (77, 39.3)
Age (years) Average 54 +/− 15 53 +/− 15 0.685 54 +/− 15
Range 21–88 21–82 21–88
Karnofsky
pre-surgery
Average 84 +/− 9 87 +/− 8 0.088 85 +/− 9
Range 70–100 70–100 70–100
Histopathology LOW GRADE (n, %) (41, 28.10) (19, 38.00) 0.189 (60, 30.6)
Pilocytic Astrocytoma 13, 31.7 4, 21.1 17, 28.3
Diffuse astrocytoma 10, 24.4 3, 15.8 13, 21.6
Oligodendroglioma 12, 29.3 10, 52.6 22, 36.6
Pleomorphic Xanthoastrocytoma 3, 7.3 0, 0 3, 5.0
Chordoid Glioma 1, 2.4 1, 5.3 2, 3.3
Angiocentric glioma 2, 4.9 1, 5.3 3, 5.0
HIGH GRADE (n, %) (105, 71.90) (31, 62.00) (136, 69.4)
Glioblastoma Multiforme 76, 72.4 24, 77.4 100, 76.9
Anaplastic Astrocytoma 9, 8.6 1, 3.2 10, 7.7
Anaplastic Oligodendroglioma 14, 13.3 4, 12.9 18, 13.8
Gliosarcoma 4, 3.8 2, 6.5 6, 4.6
Meduloblastoma 2, 1.9 0, 0 2, 1.5
Reintervention Yes (n, %) (0, 0) (4, 8) 0.283 (4, 2)November 2020 | Volume 10 | ArtiNS, No statistically significant at 5%.cle 586679
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significant result (p = 0.03) (Figure 1A). In addition, our study
demonstrated the benefits of LF-iMR by means of the novel R-
KPS effectiveness variable, since there was a significant increase
in terms of number of patients in which a subtotal or GTR was
obtained without worsening their pKPS in the intervention
group (52% vs.35%; SD: 10.4; p = 0.039) (Table 3). As
previously noted, this improvement did not have a significant
impact on the 1-year and 2-year OS rates. Kaplan-Meyer curves
were created to illustrate the OS and mortality rate for HGG in
both cohorts (Figure 1B). Mortality rate at 1 and 2 years for LGG
was 0 in both groups.Frontiers in Oncology | www.frontiersin.org 5Resource Use and Costs
Regarding the use of resources, we stated a significant reduction
in the LoS (9.7 vs. 11.9, p < 0.05) for patients in the LF-iMR
group (Table 1). However, the cost per surgery was higher in the
intervention group (+2,182 Euro). These costs are mainly due to
the implementation of certain expendables and to longer surgical
times. However, within the LF-iMR group there was a downward
trend in surgical times as experience was progressively acquired
which contributed to alleviate the overall cost due to operating
room usage (Figure 2).A
B
FIGURE 1 | Kapplan-Meier survival curves. (A) Progression-free survival
curves for LF-iMR and Conventional surgery cohorts. (B) Kapplan-Meier
survival curves for high grade glioma patients.TABLE 3 | Clinical outcomes and costs per intervention by resource use.
Conventional
OR
LF-iMR LF-iMR-
Conventional
OR)
p-value
Clinical outcomes
Gross Total Resection
(%)a
56.2 70.0 13.8 0.121
Complications (%)b 21.3 14.0 −7.3 0.639
Postoperative
KPS*
77 +/− 18 84 +/−
8
7 0.000
Range 60–100 60–100
1-year OS (%) 84.3 88 3.7 0.874
2-years OS (%) 73.3 70 −3.3 0.744
R-KPS (%)c,* 35 52 17 0.039
1-year PFS (days) 295 333 38 0.025
Costs per intervention
Operating Room 3,356 € 5,162 1,806 0.0000
ICU 717 € 472 € −245 € 0.0375
Diagnostic images 1,269 € 1,082 € −186 € 0.0473
Hospitalization 5,087 € 4,177 € −910 € 0.0332November 2020 | Volume 10 | ArticICU, Intensive Care Unit; KPS, Karnofsky performance status; OS, overall survival; PFS,
Progression-free survival; R-KPS, Resection and postoperative KPS.
*Effectiveness measures considered in the cost-effectiveness analysis.
aPercentage of patients.
bPercentage of patients who suffered one or more complications.
cPercentage of patients presenting with a Subtotal or Gross total resection and an equal or
higher postoperative KPS.FIGURE 2 | Surgical times per patient. The graphic illustrates the downward
trend in surgical times progressively achieved in the LF-iMR group.le 586679
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The results of the cost-effectiveness analysis showed a mean
incremental cost per patient estimated in 789 € when the LF-iMR
was used. Higher costs in the LF-iMR group were mainly due
operating room usage; while ICU, diagnostic imaging and
hospitalization costs were lower (Table 3). ICERs were 111 €
per additional point of pKPS, 46 € per additional percentage
point in the R-KPS and 21 € per additional day free of
progression (Table 4). Therefore, the LF-iMR would be cost-
effective depending on the willingness to pay of the hospital
managers for an additional effectiveness unit. It is worth to note
that the LoS is the cost variable that most affected the cost-
effectiveness results.
According to the deterministic sensitivity analysis, the iMR
remains very close to a dominant position across the three
different scenarios (Table 5). This means that the LF-iMR it is
definitively more effective but slightly costlier than the
conventional OR. Exceptionally, in the most conservative
scenario A, where the clinical outcomes were set to be the
worst possible results, the LF-iMR is dominated by the
conventional OR in terms of KPS and 1-year PFS (i.e., costlier
and less effective); however, the LF-iMR remains very close to the
dominant position in terms of R-KPS. Regarding Scenario D, in
which the analysis included exclusively patients diagnosed with
HGG, displayed very similar results to the base case. PSA results
are summarized and illustrated in Figure 3. The ICERs (Monte
Carlo simulations) provided by the PSA for R-KPS as
effectiveness measure, are largely located (35%) in the area
(south-east quadrant of the plane) where the LF-iMR is a
dominant technology (less costly and more effective).DISCUSSION
In this article, we have conducted a cost-effectiveness analysis of
the impact of a LF-iMR in glioma surgery. The results
demonstrated a significant improvement in the subset of
patients operated with LF-iMR in terms of pKPS and in the
number of patients in which a subtotal or GTR is achieved
preserving their clinical status, but we failed to obtain statistically
significant results regarding OS. The cost-effectiveness analysis
demonstrated that the LF-iMR remained very close to a
dominant position (i.e., a less costly and more effectiveTABLE 4 | Results of the cost-effectiveness analysis.
Conventional OR LF-iMR Incremental (iMR – Conventional OR)
Cost (€ 2018) 11,599 10,810 789
Effectiveness measures Postoperative KPS 77.1 84.3 7.1
R-KPS 35 52 17
1-year PFS 295 333 38
ICER Postoperative KPS n.a. n.a. 111
R- KPS n.a. n.a. 46
1-year PFS n.a. n.a. 21NovemICER, Incremental cost-effectiveness ratio: cost per additional unit of effectiveness (per additional point of postoperative KPS, percentage point of R-KPS or days of PFS); KPS, Karnofsky
performance status; n.a., not-applicable; PFS, Progression-free survival; R-KPS, Resection and postoperative KPS.TABLE 5 | Deterministic sensitivity analysis results.
Parameter Mean Value (SD) ICER
Base Case
LF-iMR device costa,b 1,000,000 (200,000) n.a.
Cost (€ 2018) (iMR) 11,599
Cost (€ 2018) (Conv. OR) 10,810
Postoperative KPS (iMR)b 84 (9) 111
Postoperative KPS (Conv.
OR)b
77.1 (18)
R-KPS b 52 (10.4) 46
R-KPS (Conv. OR)b 35 (7)
1-year PFS (iMR)b 333 (76) 21
1-year PFS (Conv. OR)b 295 (40)
New Value on the Sensitivity
Analysis
Scenario A (conservative)c
Postoperative KPS (iMR) 75 Dominated
R-KPS 41.6 118
1-year PFS 255 Dominated
Scenario B (favorable)d
Postoperative (iMR) 93 50
R-KPS 62.4 29
1-year PFS 410 7
Scenario C (favorable)e
LF-iMR device cost 800,000e
408f
n.a.
Postoperative KPS (iMR) 84 88
R-KPS 52 36
Scenario D (HGG sub-
group)g
Cost (€ 2018) (iMR) 11,608 n.a.
Cost (€ 2018) (Conv. OR) 10,853
Postoperative KPS (iMR) 84.1 88
Postoperative KPS (Conv.
OR)
75.5
R-KPS (iMR) 55 44
R-KPS (Conv. OR) 31
1-year PFS (iMR) 322 20
1-year PFS (Conv. OR) 284ICER, Incremental cost-effectiveness ratio: cost per additional unit of effectiveness (per
additional point of postoperative KPS or percentage point of R-KPS); KPS, Karnofsky
performance status; R-KPS, Resection and postoperative KPS; SD, Standard deviation.
aTotal cost of the iMR device.
bSD is based on the variation of 20% as recommended in the international guidelines in
health economic evaluation (18).
cScenario A: Worst possible clinical outcomes of the iMR.
dScenario B: Best possible clinical outcomes of the iMR.
eScenario C: Reduction of the cost of the iMR device due to its extensive use.
fCost per intervention.
g Scenario D: Only considering the HGG cohort.ber 2020 | Volume 10 | Article 586679
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effectiveness variable (R-KPS, postoperative KPS, and 1-year
PFS). These benefits being acknowledged, whether the
incremental costs are justified or not, might be matter of an
open debate. Such a discussion involves socio-economic and
ethical considerations that go beyond the purpose of the present
article. Similar outcomes might lead to different decisions
depending, for instance, on the willingness to pay of hospitalFrontiers in Oncology | www.frontiersin.org 7managers for an additional effectiveness unit. Nevertheless, both
the deterministic and PSA provided consistent results regarding
the R-KPS.
Many groups have outlined the advantages of performing
neurooncological surgery with the assistance of an iMR (13–15,
20). Moreover, it has been consistently reported a variable
but clear upward trend in the EoR of gliomas (13, 15, 21–23).
However, the vast majority of reports have failed to demonstrateA
B
FIGURE 3 | Monte Carlo simulations for the probabilistic sensitive analysis of cost-effectiveness results. (A) KPS. ICER for the postoperative KPS is horizontally
dispersed on the plane, meaning that the results of the cost-effectiveness analysis are notably influenced by the values of this variable. (B) R-KPS. In the other hand,
ICERs for R-KPS are largely located (35%) in the area where the iMR is a dominant technology, i.e., a less costly and more effective technology than the conventional
OR. ICER, Incremental cost-effectiveness ratio; X-axis, Effectiveness measures; Y-axis, Cost in euros.November 2020 | Volume 10 | Article 586679
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been said about the costs of these technologies, and even less
about their cost-effectiveness and rationale for their
implementation in public health systems (26). In previous
publications, our group has highlighted the advantages and
limitations of a low-field compared to a high-field iMR (13–
15). Hence, in the current discussion, we will obviate differences
regarding the novelty or technical specifications of the devices
themselves. Moreover, future research in the evaluation of new
technologies in neurosurgery may reproduce our methodology
regardless of our results or the obsolescence of the technology. In
this sense, it is important to note that commercial production of
the device implemented in the present study ceased 1 year ago.
This being said, we consider that our method is reproducible and
that our results and conclusions could be useful to evaluate and
compare other intraoperative imaging technologies implemented
in neurooncological surgeries.
The available bibliography comparing conventional and LF-
iMR guided surgery for gliomas is quite scarce (25). Senft et al.
demonstrated in their randomized trial the augmentation in the
rate of GTR in HGG without any impact in postoperative
complications rates in the LF-iMR group (21). The EoR
reported by these authors was superior to ours, 96% vs. 70% in
the LF-iMR group and 68% vs. 56.2% in the conventional surgery
group. It is worth to note that our cohorts included patients with
LGG and HGG and that tumors near eloquent areas were not
excluded. Therefore, an inferior EoR could be expected
compared to those reports exclusively including contrast
enhancing lesions in non-eloquent areas (21). The experience
reported by Kubben et al. could hardly be extrapolated since their
trial was stopped with only seven patients per branch due to slow
recruitment, technical issues, and surgical time concerns (25, 27).
In this investigation, a significant decline in the LoS in the
cohort operated with LF-iMR contributed to alleviate the
incremental cost of the device itself. Various factors might
accrue to explain this reduction. First, patient’s postoperative
KPS was higher in the LF-iMR cohort, probably anticipating the
date of discharge. Second, fewer complications resulted in a
shorter ICU and in-bed stay. Finally, some of our patients are
referred from other hospitals where preoperative MRIs does not
include a study suitable for navigation. While this situation
delayed the surgery in the cohort operated in a conventional
fashion, it had no effects in the iMR cohort since their
preoperative, not suitable for navigation, study could be
merged with an immediately preoperative study acquired with
the LF-iMR. Regarding LoS other authors had reported similar
reductions, albeit they failed to achieve statistically
significance (26).
Various reports have failed to demonstrate a significant
improvement in OS in patients operated with the guidance of
an intraoperative device despite higher GTR rates (13, 20, 25, 28).
One-year analysis showed a slight decline in the mortality rate
found in the intervention group (15.75% vs. 12%). Nonetheless,
since this result was not statistically significant, we feared that it
might be due to differences in the proportion of HGG and to
short follow up. Therefore, follow up was extended to two yearsFrontiers in Oncology | www.frontiersin.org 8to check if this positive trend was sustained over time. Sadly, as
previously reported, we could only confirm that small increases
in GTR rates for HGG yields minor or none improvement in OS
rates (Figure 1). Actually, OS rate at two years was lower in the
intervention group when LGG and HGG were conjointly
considered. This fact might seem inconsistent with the
accepted statement of EoR being a major prognostic factor, it
is clear that is not the only one. Probably, other prognostic
factors such as the histological subtype, molecular biology or
availability of therapeutic targets, and adjuvant therapies might
play a more significant role (29–34).
In the present study, differences on PFS between both cohorts
reached statistical significance. Our data are in line with previous
reports in which conventional surgery and complete adjuvant
therapy were implemented to achieve a mean PFS of
approximately 9 months in HGG (35). Our PFS is superior to
this figure in both cohorts probably due to the coexistence of
HGG and LGG in each group. Previous reports evaluating
the effectiveness of iMR devices failed to demonstrate
significant changes on PFS (36). However, positive trends
on the improvement of PFS had been linked to the use of
intraoperative imaging tools (10, 36, 37) as a result of an
increase in the EoR (35, 38, 39).
Regarding the selection of effectiveness variables, it is worth
to note that 1-year PFS and KPS have been extensively
employed and validated as adequate effectiveness variables.
However, R-KPS, as a novel variable, has not previously been
implemented in neuro-oncology studies and would require
further validation. EoR was not considered as an effectiveness
variable according to WHO recommendations which state that
effectiveness should be evaluated by a variable that quantifies
the gain of health (40). EoR is not an actual gain of health unlike
KPS, PFS, or OS.
This clinical investigation harbors various limitations that
should be disclosed. The hybrid design of the recruitment might
involve a selection bias since patients were not randomly allocated
to either group. In addition, both cohorts are made up of LGG and
HGG, which confers a great clinical, radiological and prognostic
heterogeneity that could be detrimental for the quality of the study.
Actually, the range of diagnoses included in each cohort could
independently affect the results reported. However, we sought to
assess the effectiveness and implications of adding up a new device
to the conventional surgical armamentarium. Therefore, we
considered that the effects of surgery on LGG and HGG were
comparable. Indeed, we limited our observations to 1 year, not to
distort the effects of surgery with those owed to the intrinsic nature
of tumors and adjuvant therapies. This decision limited the analysis
of cost-effectiveness analysis regarding OS and PFS to 1 year since
data of costs per patient were available just for one-year frame,
which might be a short period, especially for LGG. Patients were
operated by the same surgical team in both cohorts; therefore,
differences in the clinical outcomes between groups should not be
imputed to any improvement in the surgical technique. However,
there may exist uncontrolled biases due to the retrospective
collection of the historical cohort and unnoticed changes on
surgical technique throughout the time frame of this study.November 2020 | Volume 10 | Article 586679
Garcia-Garcia et al. iMR Cost-Effectiveness in Glioma SurgeryIt might be argued that the design of the study downsizes the
level of evidence of this clinical investigation. A prospective
controlled trial would be the proper design to support with the
highest level of evidence the conclusions herein stated (41).
However, randomized controlled trials are often not adequate
for neurological surgery since surgical trials are unmasked,
surgical skills are not constant, lack of equipoise in decision
makers, low-caseload diseases, slow recruitment, results in
selection biases, and tremendous difficulties to obtain well-
matched groups after randomization (42–44). In addition, the
hybrid, retrospective and prospective, collection of patients did
not allow the performance of a propensity score matching
analysis. Thus, our approach sought to minimize biases while
providing patients with the best possible treatment. At the
moment of design of this research, the available bibliography
on LF-iMR guided surgery was scarce; however, we considered
it would not have been ethical to allocate patients randomly.
Previous experience in intraoperative image guiding tools such
as neuronavigation or CT scans suggested that LF-iMR could be
useful, safe, and would result in similar or better surgical results
compared to conventional surgery. Therefore, despite the
limitations, our methodology responds to give patients the
standard of care, to maintain an ethical perspective by
providing a potentially beneficial treatment while achieving
an acceptable level of evidence.
Regarding the cost-effectiveness analysis, patient perspective
was indirectly considered by assessing clinical variables.
However, since differences in patient complications and in 1-
year survival were not statistically significant, these two variables
were not included in the cost-effectiveness analysis. It might also
be argued that Health-Related Quality of Life (HRQoL) should
have been assessed before and after the intervention in order to
provide effectiveness outcomes in terms of Quality-Adjusted Life
Years (QALYs). This kind of measurements are often
recommended to suggest more accurate and specific
recommendations relying in country-specific cost-effectiveness
thresholds (45).CONCLUSION
The present clinical research is, to the best of our knowledge,
the first to provide evidence in terms of cost-effectiveness
regarding LF-iMR implementation for glioma surgery. The
guidance of an LF-iMR contributed to improve the clinical
and surgical outcomes of the patients in which it was used.
Despite the initially promising results in the LF-iMR cohort,
they did not come along with significant higher survival rates.
Therefore, we could conclude that patients operated under the
guidance of a LF-iMR device achieve greater resections with less
complications, better PFS rates but similar life expectancy. The
LF-iMR is very close to be a dominant technology compared to
conventional surgery in terms of R-KPS, pKPS, and 1-year PFS.
These results are supported by the sensitivity analyses in terms
of R-KPS, in which a dominant position of the LF-iMR seemsFrontiers in Oncology | www.frontiersin.org 9largely plausible. Summarizing, in the light of our results, we
recommend the use of LF-iMR as a cost-effective technology to
achieve better outcomes in terms of R-KPS. However, for the
rest of effectiveness, variables further research involving bigger
cohorts and longer follow-up is required.DATA AVAILABILITY STATEMENT
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